Stem cell transplant or rescue: patient has not had a prior stem cell transplant or rescue
No prior treatment with high-dose chemotherapy (defined as treatment utilizing stem cell rescue)
Patient must be >= 3 months since high dose chemotherapy and peripheral blood stem cell rescue prior to registration
Previous high-dose chemotherapy requiring stem cell rescue.
Must not be eligible for high-dose therapy with autologous stem cell transplantation rescue
Prior high dose chemotherapy requiring stem cell rescue.
Histologically confirmed non-Hodgkin lymphoma and be considered ineligible for standard curative therapeutic options, including high dose chemotherapy with autologous stem cell rescue
Previous high-dose chemotherapy requiring allogenic stem cell rescue.
Patients who have received any of the following:\r\n* > 2 chemotherapy regimens\r\n* Myeloablative chemotherapy with stem cell rescue\r\n* Craniospinal irradiation
Previous high-dose chemotherapy requiring stem cell rescue
Eligible for high-dose therapy and autologous stem-cell rescue
Comorbid condition(s) which, in the opinion of the attending physician and/or MSK Cancer Center (CC) principal investigator, will preclude stem cell mobilization and/or high-dose therapy with autologous stem cell rescue
Meets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those procedures
Patients must have a minimum stem cell dose of 4x10^6 CD34+ MNC/kg stored for autologous stem cell rescue
Treatment with high-dose chemotherapy and hematopoietic stem-cell rescue within 3 months prior to initiation of study drug
High-dose chemotherapy with stem-cell rescue: interval >= 3 months before study enrollment
Patients with multiple myeloma who are potential candidates for high dose chemotherapy with stem cell rescue
Scheduled to receive stem cell rescue therapy in conjunction with study related course(s) of emetogenic chemotherapy
Frequent use of rescue opioids > 8 x/day or rescue bronchodilators > 8 x/day over last 24 hours
Approved rescue medication for the treatment of nausea and vomiting is permitted at the discretion of the investigator; the rescue antiemetics allowed will include: ondansetron, granisetron and lorazepam
Will be receiving stem cell rescue therapy in conjunction with study-related course of emetogenic chemotherapy or during the 14 days following administration of fosaprepitant/placebo for fosaprepitant
Patients with a history of organ transplant including high dose chemotherapy with autologous stem cell rescue